[Heart failure in a subject treated with anthracyclines in childhood: myocardial dysfunction is not always the only reason of it].
Anthracyclines, found to be efficacious in the treatment of a broad spectrum of pediatric malignancies, are cardiotoxic and may lead to heart failure even a long time after successful treatment of cancer. It is thought that subtle abnormalities can progress to the more permanent myocardial disease, resulting in cardiomyopathy which may progress to congestive heart failure. There are some precipitating factors leading to the sudden onset of cardiac symptoms such as increase in afterload or preload. We describe a young patient with congestive heart failure treated with doxorubicin (cumulative mean dose 420 mg/m2) in infancy because of pelvic sarcoma in whom the appearance of symptoms was related to pulmonary embolism. Four years before hospital admission, the patient presented echocardiographic abnormalities such as left ventricular fractional shortening and thickness reduction and he was treated with ACE-inhibitors. The myocardial ischemia, which is present in pulmonary embolism, probably worsened the left ventricular systolic function and caused congestive heart failure.
Iarussi
Diana
D
Cattedra di Cardiologia, Dipartimento di Scienze Cardiotoraciche e Respiratorie, Seconda Università degli Studi, Napoli. dianal.iarussi@unina2.it
Martino
Vincenzo
V
Iacono
Carola
C
Indolfi
Paolo
P
Muto
Roberto
R
Calabrò
Raffaele
R
D000293:Adolescent; D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male; D012509:Sarcoma / Q000188:drug therapy
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin